SiBone (SIBN) Expected to Post Earnings on Monday

SiBone (NASDAQ:SIBN) is anticipated to announce its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect SiBone to announce earnings of ($0.13) per share and revenue of $55.31 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

SiBone (NASDAQ:SIBN) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.06. The business had revenue of $56.01 million for the quarter, compared to the consensus estimate of $55.34 million. SiBone had a negative return on equity of 8.23% and a negative net margin of 6.85%. On average, analysts expect SiBone to post ($0.40) EPS for the current fiscal year and ($0.33) EPS for the next fiscal year.

SiBone Price Performance

NASDAQ:SIBN opened at $21.48 on Monday. The firm has a market capitalization of $952.64 million, a price-to-earnings ratio of -63.18 and a beta of 0.66. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. The business’s fifty day moving average price is $19.16 and its 200 day moving average price is $16.85.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on SIBN shares. Truist Financial upped their target price on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. TD Cowen upped their price objective on shares of SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Weiss Ratings upgraded shares of SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Finally, UBS Group increased their target price on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $24.50.

Insider Transactions at SiBone

In other SiBone news, insider Anshul Maheshwari sold 1,731 shares of the company’s stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $19.50, for a total value of $33,754.50. Following the transaction, the insider directly owned 218,235 shares of the company’s stock, valued at $4,255,582.50. This represents a 0.79% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Laura Francis sold 38,006 shares of the company’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $20.05, for a total value of $762,020.30. Following the completion of the transaction, the chief executive officer directly owned 379,256 shares in the company, valued at approximately $7,604,082.80. The trade was a 9.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 224,968 shares of company stock worth $4,368,118 in the last ninety days. Company insiders own 4.00% of the company’s stock.

About SiBone

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.